Novel biologics that aim to offer freedom from disease to
people with plaque psoriasis and other associated conditions

Who
We Are

Oruka is our name and our mission—derived from or, for “skin,” and arukah, for “restoration.” We are seasoned biopharma professionals and drug developers committed to improving the experiences of people living with plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications.

Several thin blue lines grouped together winding in wave formation around text.

Our
Pipeline

We are advancing potentially best-in-class monoclonal antibodies designed to set a new treatment standard for psoriasis and other related diseases by delivering higher rates of complete disease clearance with as few as one or two doses per year.

Latest
News

09.23.2026

Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

Join Us

We seek passionate people to help us bring healthy skin within reach for those living with chronic disorders.